According to the company's statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in the patients.
Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results